Thyroid function abnormalities in patients receiving VEGF-targeted therapy

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 4, 2011, Pages 337-338

  Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

DRUG INDUCED DISEASE; EUTHYROIDISM; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPOTHYROIDISM; INCIDENCE; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; PATHOGENESIS; REVIEW; THYROID DISEASE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; METASTASIS; NOTE; PATHOPHYSIOLOGY; THYROID GLAND;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; HYPOTHYROIDISM; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PYRIDINES; THYROID GLAND; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79955726432     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Block MS, Kohli M. Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. Clin Adv Hematol Oncol. 2011;9:335-337.
2. Miyake H, Kurahashi T, Yamanaka K, et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol. 2010;28:515-519.
3. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81-83.
4. Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol. 2008;19:265-268.
5. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145: 660-664.
6. Riesenbeck LM, Bierer S, Hoffmeister I, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 2010 Dec 14. [Epub ahead of print].
7. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med. 2007;356:125-134.
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
9. Sato S, Muraishi K, Tani J, et al. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J. 2010;57:873-880.
10. Shinohara N, Takahashi M, Kamishima T, et al. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer. 2011;104:241-247.
11. Schmidinger M Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: Blessing or curse? Cancer. 2011;117:534-544.